RECORDATI : FINALIZES THE FIRST TRANCHE OF ITS ACQUISITION OF OPALIA PHARMA IN TUNISIA
(Thomson Reuters ONE) -
Milan, 31 October 2013 - Recordati announces the successful conclusion of the
acquisition of approximately 67% of the share capital of Opalia Pharma S.A., a
Tunisian pharmaceutical company with headquarters in Ariana, a suburb of Tunis.
This first tranche consists of the portion of the share capital held by non-
Tunisian shareholders, one of which is The Abraaj Group. An amount of ? 22.6
million were paid at the closing. The conclusion of the acquisition of a further
23% is expected to take place in the coming months.
Opalia Pharma was established in 1988, ranks eighth in the Tunisian
pharmaceutical market and is the third largest local pharmaceutical company. The
company markets branded generic drugs with leading products in dermatology and
in the gastrointestinal and respiratory therapeutic areas. Opalia manufactures
most of its products in a modern, cGMP certified production facility specialized
in liquid and semi-solid forms. The company employs around 320 people and
generates annual sales of around TND 40 million (around ? 18 million).
Recordati, established in 1926, is an international pharmaceutical group, listed
on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT
0003828271), with a total staff of over 3,300, dedicated to the research,
development, manufacturing and marketing of pharmaceuticals. Headquartered in
Milan, Italy, Recordati has operations in the main European countries, in
Russia, in other Central and Eastern European countries, in Turkey and in the
United States of America. A field force of more than 1,700 medical
representatives promotes a wide range of innovative pharmaceuticals, both
proprietary and under license, in a number of therapeutic areas including a
specialized business dedicated to treatments for rare diseases. Recordati is a
partner of choice for new product licenses for its territories. Recordati is
committed to the research and development of new drug entities within the
cardiovascular and urogenital therapeutic areas and of treatments for rare
diseases. Consolidated revenue for 2012 was ? 828.3 million, operating income
was ? 167.0 million and net income was ? 118.5 million.
For further information:
Recordati website: www.recordati.com
Investor Relations Media
Relations
Marianne Tatschke
Ketchum
(39)0248787393 Cristina Risciotti,
(39)0262411919, cristina.risciotti(at)ketchum.com
e-mail: inver(at)recordati.it Marzia
Ongaretti, (39)0262411915,
marzia.ongaretti(at)ketchum.com
Statements contained in this release, other than historical facts, are "forward-
looking statements" (as such term is defined in the Private Securities
Litigation Reform Act of 1995). These statements are based on currently
available information, on current best estimates, and on assumptions believed to
be reasonable. This information, these estimates and assumptions may prove to be
incomplete or erroneous, and involve numerous risks and uncertainties, beyond
the Company's control. Hence, actual results may differ materially from those
expressed or implied by such forward-looking statements. All mentions and
descriptions of Recordati products are intended solely as information on the
general nature of the company's activities and are not intended to indicate the
advisability of administering any product in any particular instance.
RECORDATI FINALIZES THE FIRST TRANCHE OF ITS ACQUISITION OF OPALIA PHA:
http://hugin.info/143644/R/1739671/583970.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: RECORDATI via Thomson Reuters ONE
[HUG#1739671]
Unternehmensinformation / Kurzprofil:
Datum: 31.10.2013 - 14:51 Uhr
Sprache: Deutsch
News-ID 311469
Anzahl Zeichen: 4722
contact information:
Town:
MILANO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 235 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"RECORDATI : FINALIZES THE FIRST TRANCHE OF ITS ACQUISITION OF OPALIA PHARMA IN TUNISIA"
steht unter der journalistisch-redaktionellen Verantwortung von
RECORDATI (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
